Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

FDA Grants Priority Review to Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible MIBC

October 23rd 2025

The FDA granted priority review to enfortumab vedotin plus pembrolizumab as perioperative therapy for cisplatin-ineligible muscle-invasive bladder cancer.

Dr Gupta on Responses With Enfortumab Vedotin/Pembrolizumab in Urothelial Carcinoma

October 22nd 2025

Shilpa Gupta, MD, discusses response and subgroup data with enfortumab vedotin plus pembrolizumab in locally advanced/ metastatic urothelial carcinoma.

Atezolizumab Plus BCG Does Not Improve EFS Vs BCG Alone in BCG-Naive NMIBC

October 22nd 2025

Atezolizumab plus BCG did not extend EFS vs BCG alone in BCG-naive, high-risk non–muscle invasive bladder cancer.

Breaking Down the Data in Bladder Cancer With Drs Aggen, Grivas, and Shore

October 21st 2025

David H. Aggen, MD, PhD, Petros Grivas, MD, PhD, and Neal Shore, MD, FACS, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in bladder cancer presented during the 2025 ESMO Congress.

ctDNA-Guided Adjuvant Atezolizumab Boosts DFS, OS in Muscle-Invasive Bladder Cancer

October 20th 2025

Adjuvant atezolizumab improved DFS and OS in patients with muscle-invasive bladder cancer who tested positive for ctDNA after radical cystectomy.

First-Line Disitamab Vedotin Plus Toripalimab Yields Survival Advantage in HER2+ Advanced Urothelial Cancer

October 19th 2025

Frontline disitamab vedotin plus toripalimab significantly improved PFS and OS in HER2-expressing locally advanced or metastatic urothelial carcinoma.

Perioperative Enfortumab Vedotin Plus Pembrolizumab May Represent New SOC in Cisplatin-Ineligible MIBC

October 18th 2025

Enfortumab vedotin plus pembrolizumab significantly improved survival and pCR vs surgery alone in cisplatin-ineligible MIBC per KEYNOTE-905 data.

Dato-DXd Plus Rilvegostomig Elicits Activity in Cisplatin-Ineligible or Platinum-Pretreated Urothelial Cancer

October 18th 2025

Datopotamab deruxtecan plus rilvegostomig was active in cisplatin-ineligible and platinum-pretreated locally advanced or metastatic urothelial cancer.

SunRISe-4 Data Support Role for Neoadjuvant Gemcitabine Intravesical System Plus Cetrelimab in MIBC

October 17th 2025

SunRISe-4 data show that TAR-200 and cetrelimab led to a high pCR and 12-month RFS rate in muscle-invasive bladder cancer.

Adjuvant Nivolumab Generates Long-Term DFS Benefit in Resected MIUC

October 17th 2025

Five year follow up results from CheckMate 274 support adjuvant nivolumab as a standard of care for high-risk muscle-invasive urothelial carcinoma.

Dr Gupta on the Efficacy of Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma

October 15th 2025

Shilpa Gupta, MD, discusses the clinical effects of findings from the phase 3 EV-302/KEYNOTE-A39 trial in locally advanced/metastatic urothelial carcinoma.

Izalontamab Brengitecan Data Reinforce the Value of ADCs in Advanced Urothelial Carcinoma

October 15th 2025

Izalontamab brengitecan showed signals of activity in patients with pretreated locally advanced or metastatic urothelial carcinoma.

FDA Approval of TAR-200 Represents Potential Bladder-Sparing Option in BCG-Unresponsive NMIBC

October 15th 2025

Joseph Jacob, MD, MCR, discusses the significance of the FDA approval of TAR-200 for BCG-unresponsive non–muscle-invasive bladder cancer.

FDA Approval Insights: Gemcitabine Intravesical System for NMIBC: With Joseph Jacob, MD, MCR

October 9th 2025

Dr Jacob discusses the significance of the FDA approval of the gemcitabine intravesical system for BCG-unresponsive non–muscle-invasive bladder cancer.

Urothelial Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025

October 8th 2025

Check out this September recap of OncLive’s coverage of the top news and expert insights in urothelial cancer.

Dr Martini on the Mechanism of Action of Cretostimogene Grenadenorepvec in Urothelial Carcinoma

October 3rd 2025

Alberto Martini, MD, discusses cretostimogene grenadenorepvec in urothelial carcinoma.

OncLive’s September Roundup of Key FDA Approvals in Oncology: 4 Decisions to Know

October 3rd 2025

Here is your guide to all therapeutic options that were approved by the FDA in September 2025 spanning tumor types.

Poll: Vote on the Top Lung, GU Cancer Abstracts to Watch at ESMO 2025

September 22nd 2025

Vote in OncLive's polls to share which lung and genitournary cancer abstracts you're most anticipating at the 2025 ESMO Congress.

FDA Approves Subcutaneous Pembrolizumab for Solid Tumors

September 19th 2025

The FDA approved subcutaneous pembrolizumab for use in adult and pediatric solid tumor indications approved for intravenous pembrolizumab.

Nadofaragene Firadenovec NDA Accepted for Review in Japan for BCG-Unresponsive NMIBC

September 15th 2025

A new drug application for nadofaragene firadenovec in BCG-unresponsive bladder cancer has been accepted for review in Japan.